MustGrow Biologics Corp (CSE: MGRO) is looking to potentially expand the effective diseases in which its flagship mustard-derived technology is proven to be effective against. This morning, the firm announced the commencement of testing of its product against that of clubroot, which is a disease pathogen that is destroying high value canola crops at an alarming rate.
Clubroot is a soil-borne disease that is a fungus-like organism. The disease causes swelling and galls to form on the root of canola plants, which leads to premature death of the plant. Currently, there are no economically viable control measures for the disease, which can lead up to a 100% crop loss after infection.
With MustGrow’s current mustard-derived tech proven to be effective against soil-borne diseases such as Fusarium, Botrytis, Rhizoctonia, Pythium, Verticillium, Phytophthora, Sclerotinia, and Nematodes, the additional testing will determine if the product is also effective against the currently spreading disease of clubroot. MustGrow’s bio-pesticide has been proven to be safer than synthetically-derived alternatives currently on the market for tackling these numerous soil-borne diseases.
MustGrow Biologics last traded at $0.48 on the CSE.
FULL DISCLOSURE: MustGrow Biologics Corp is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover MustGrow Biologics Corp on The Deep Dive, with The Deep Dive having full editorial control. Additionally, the author personally holds securities of the company and may buy or sell at any future point in time. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.